HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Abstract
PURPOSE Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety of pazopanib monotherapy in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). PATIENTS AND METHODS Adult patients with measurable, locally advanced, and/or metastatic RCC were randomly assigned 2:1 to receive oral pazopanib or placebo. The primary end point was progression-free survival (PFS). Secondary end points included overall survival, tumor response rate (Response Evaluation Criteria in Solid Tumors), and safety. Radiographic assessments of tumors were independently reviewed. Results Of 435 patients enrolled, 233 were treatment naive (54%) and 202 were cytokine pretreated (46%). PFS was significantly prolonged with pazopanib compared with placebo in the overall study population (median, PFS 9.2 v 4.2 months; hazard ratio [HR], 0.46; 95% CI, 0.34 to 0.62; P < .0001), the treatment-naive subpopulation (median PFS 11.1 v 2.8 months; HR, 0.40; 95% CI, 0.27 to 0.60; P < .0001), and the cytokine-pretreated subpopulation (median PFS, 7.4 v 4.2 months; HR, 0.54; 95% CI, 0.35 to 0.84; P < .001). The objective response rate was 30% with pazopanib compared with 3% with placebo (P < .001). The median duration of response was longer than 1 year. The most common adverse events were diarrhea, hypertension, hair color changes, nausea, anorexia, and vomiting. There was no evidence of clinically important differences in quality of life for pazopanib versus placebo. CONCLUSION Pazopanib demonstrated significant improvement in PFS and tumor response compared with placebo in treatment-naive and cytokine-pretreated patients with advanced and/or metastatic RCC.
AuthorsCora N Sternberg, Ian D Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H Barrios, Pamela Salman, Oleg A Gladkov, Alexander Kavina, Juan J Zarbá, Mei Chen, Lauren McCann, Lini Pandite, Debasish F Roychowdhury, Robert E Hawkins
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 28 Issue 6 Pg. 1061-8 (Feb 20 2010) ISSN: 1527-7755 [Electronic] United States
PMID20100962 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Indazoles
  • Placebos
  • Pyrimidines
  • Sulfonamides
  • pazopanib
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms (drug therapy, secondary)
  • Carcinoma, Renal Cell (drug therapy, secondary)
  • Double-Blind Method
  • Female
  • Humans
  • Indazoles
  • International Agencies
  • Kidney Neoplasms (drug therapy, pathology)
  • Liver Neoplasms (drug therapy, secondary)
  • Lung Neoplasms (drug therapy, secondary)
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Placebos
  • Prognosis
  • Pyrimidines (therapeutic use)
  • Sulfonamides (therapeutic use)
  • Survival Rate
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: